JP2013538857A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538857A5
JP2013538857A5 JP2013531861A JP2013531861A JP2013538857A5 JP 2013538857 A5 JP2013538857 A5 JP 2013538857A5 JP 2013531861 A JP2013531861 A JP 2013531861A JP 2013531861 A JP2013531861 A JP 2013531861A JP 2013538857 A5 JP2013538857 A5 JP 2013538857A5
Authority
JP
Japan
Prior art keywords
crystalline oxalate
composition
crystalline
salt
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013531861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538857A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/053997 external-priority patent/WO2012044825A1/en
Publication of JP2013538857A publication Critical patent/JP2013538857A/ja
Publication of JP2013538857A5 publication Critical patent/JP2013538857A5/ja
Ceased legal-status Critical Current

Links

JP2013531861A 2010-09-30 2011-09-29 ジアミド化合物の結晶性シュウ酸塩 Ceased JP2013538857A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38814810P 2010-09-30 2010-09-30
US61/388,148 2010-09-30
PCT/US2011/053997 WO2012044825A1 (en) 2010-09-30 2011-09-29 Crystalline oxalate salts of a diamide compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015111163A Division JP2015155470A (ja) 2010-09-30 2015-06-01 ジアミド化合物の結晶性シュウ酸塩

Publications (2)

Publication Number Publication Date
JP2013538857A JP2013538857A (ja) 2013-10-17
JP2013538857A5 true JP2013538857A5 (enExample) 2014-09-04

Family

ID=44903347

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013531861A Ceased JP2013538857A (ja) 2010-09-30 2011-09-29 ジアミド化合物の結晶性シュウ酸塩
JP2015111163A Pending JP2015155470A (ja) 2010-09-30 2015-06-01 ジアミド化合物の結晶性シュウ酸塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015111163A Pending JP2015155470A (ja) 2010-09-30 2015-06-01 ジアミド化合物の結晶性シュウ酸塩

Country Status (19)

Country Link
US (1) US8697724B2 (enExample)
EP (1) EP2621917A1 (enExample)
JP (2) JP2013538857A (enExample)
KR (1) KR20130139919A (enExample)
CN (1) CN103140485B (enExample)
AR (1) AR083115A1 (enExample)
AU (1) AU2011308770B2 (enExample)
BR (1) BR112013007062A2 (enExample)
CA (1) CA2810896A1 (enExample)
CL (1) CL2013000870A1 (enExample)
CO (1) CO6700846A2 (enExample)
EA (1) EA022018B1 (enExample)
IL (1) IL224985A (enExample)
MX (1) MX2013003558A (enExample)
NZ (1) NZ608721A (enExample)
PH (1) PH12013500567A1 (enExample)
SG (1) SG188390A1 (enExample)
TW (1) TW201217338A (enExample)
WO (1) WO2012044825A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
EP2067784A3 (en) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
WO2004089892A2 (en) * 2003-04-01 2004-10-21 Theravance, Inc. Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity
WO2005080375A1 (en) 2004-02-13 2005-09-01 Theravance, Inc. Crystalline form of a biphenyl compound
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
PT2599778T (pt) * 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2

Similar Documents

Publication Publication Date Title
EA022018B1 (ru) Кристаллические оксалатные соли диамидного соединения
JP2012533550A5 (enExample)
JP2009535340A5 (enExample)
JP2008513358A5 (enExample)
JP2009526018A5 (enExample)
JP2014515351A5 (enExample)
JP2016500111A5 (enExample)
RU2007109598A (ru) Кристаллическая форма бифенильного соединения
SA521430920B1 (ar) P2x3 مشتقات أمينو كينازولين كمثبطات
JP2014097964A5 (enExample)
JP2014518268A5 (enExample)
JP2014515013A5 (enExample)
JP2016527220A5 (enExample)
JP2015145426A5 (enExample)
MY159172A (en) Inhalable particles comprising tiotropium
JP2011144201A5 (enExample)
JP2008543860A5 (enExample)
HRP20100035T1 (hr) Kristalni oblici bifenilnog spoja
HRP20171304T1 (hr) Sol s jantarnom kiselinom 1-[2-(2-klor-4-{[(r)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokinolin-5-il)etilaminometil]}-5-metoksifenilkarbamoil)etil]piperidin-4-ilnog estera bifenil-2-ilkarbaminske kiseline i njezina upotreba u liječenju plućnih poremećaja
JP2015510916A5 (enExample)
JP2020518582A5 (enExample)
JP2011500621A5 (enExample)
JP2015509075A5 (enExample)
JP2016529306A5 (enExample)
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose